Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3494
| Subject | Predicate | Object | Context |
|---|---|---|---|
| dailymed-drugs:3494 | rdf:type | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:3494 | rdf:type | dailymed-instance:drugs | lld:dailymed |
| dailymed-drugs:3494 | rdfs:label | Hydrocortisone (Tablet) | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:dosage | The initial dosage of hydrocortisone tablets may vary from 20 mg to 240 mg of hydrocortisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, hydrocortisone should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of hydrocortisone for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually, rather than abruptly.<br/>Multiple Sclerosis: In treatment of acute exacerbations of multiple sclerosis, daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day for 1 month have been shown to be effective (20 mg of hydrocortisone is equivalent to 5 mg of prednisolone). | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:descripti... | Hydrocortisone Tablets, USP contain hydrocortisone which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Hydrocortisone USP is white to practically white, odorless, crystalline powder with a meltingpoint of about 215��C. It is very slightly soluble in water and in ether; sparingly soluble in acetone and in alcohol; slightly soluble in chloroform. The chemical name for hydrocortisone is pregn-4-ene-3,20-dione,11,17,21-trihydroxy-,(11��)-. Its molecular weight is 362.46 and the structural formula is as outlined below. Hydrocortisone tablets are available for oral administration in three strengths: each tablet contains either 5 mg, 10 mg, or 20 mg of hydrocortisone. Inactive ingredients: colloidal silicon dioxide, lactose, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, sodium starch glycolate. | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:activeIng... | dailymed-ingredient:Hydroco... | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:contraind... | Systemic fungal infections and known hypersensitivity to components | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:supply | Hydrocortisone Tablets, USP are available in the following strengths and package sizes: 5 mg (white, round, scored, debossed "3578" on one side and debossed "V" on the reverse side) Bottles of 10, 50, 100, 1000 10 mg (white, round, scored, debossed "3579" on one side and debossed "V" on the reverse side) Bottles of 10, 100, 1000 20 mg (white, round, scored, debossed "3580" on one side and debossed "V" on the reverse side) Bottles of 10, 100, 1000 Store at 20��to 25��C (68��to 77��F) [see USP Controlled Room Temperature]. | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:genericDr... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:activeMoi... | dailymed-ingredient:hydroco... | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:inactiveI... | dailymed-ingredient:lactose | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:inactiveI... | dailymed-ingredient:magnesi... | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:inactiveI... | dailymed-ingredient:sodium_... | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:inactiveI... | dailymed-ingredient:sodium_... | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:inactiveI... | dailymed-ingredient:silicon... | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:inactiveI... | dailymed-ingredient:cellulo... | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:possibleD... | diseasome-diseases:272 | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:possibleD... | diseasome-diseases:2013 | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:possibleD... | diseasome-diseases:116 | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:possibleD... | diseasome-diseases:851 | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:possibleD... | diseasome-diseases:710 | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:possibleD... | diseasome-diseases:3047 | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:possibleD... | diseasome-diseases:121 | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:possibleD... | diseasome-diseases:1498 | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:possibleD... | diseasome-diseases:1519 | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:possibleD... | diseasome-diseases:3398 | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:precautio... | General Precautions: Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis. Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation. The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual. Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis. Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed. Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect . Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.<br/>Information for the Patient: Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chicken pox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay. | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:genericMe... | hydrocortisone | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:fullName | Hydrocortisone (Tablet) | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:adverseRe... | Fluid and Electrolyte Disturbances Sodium retention Fluid retention Congestive heart failure in susceptible patients Potassium loss Hypokalemic alkalosis Hypertension Musculoskeletal Muscle weakness Steroid myopathy Loss of muscle mass Osteoporosis Vertebral compression fractures Aseptic necrosis of femoral and humeral heads Pathologic fracture of long bones Gastrointestinal Peptic ulcer with possible perforation and hemorrhage Pancreatitis Abdominal distention Ulcerative esophagitis Dermatologic Impaired wound healing Thin fragile skin Petechiae and ecchymoses Facial erythema Increased sweating May suppress reactions to skin tests Neurological Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment Convulsions Vertigo Headache Endocrine Development of Cushingoid state Suppression of growth in children Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness Menstrual irregularities Decreased carbohydrate tolerance Manifestations of latent diabetes mellitus Increased requirements for insulin or oral hypoglycemic agents in diabetics Ophthalmic Posterior subcapsular cataracts Increased intraocular pressure Glaucoma Exophthalmos Metabolic Negative nitrogen balance due to protein catabolism | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:warning | In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Corticosteroids may mask some signs of infection, and new infections may appear during their use. There may be decreased resistance and inability to localize infection when corticosteroids are used. Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses. Usage in Pregnancy: Since adequate human reproduction studies have not been done with corticosteroids, the use of these drugs in pregnancy, nursing mothers or women of childbearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy, should be carefully observed for signs of hypoadrenalism. Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. While on corticosteroid therapy patients should not be vaccinated against smallpox. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially in high doses, because of possible hazards of neurological complications and lack of antibody response. The use of hydrocortisone tablets in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen. If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis. Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in nonimmune children or adults on corticosteroids. In such children or adults who have not had these diseases, particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known. The contribution of the underlying diseaseand/or prior corticosteroid treatment to the risk is also not known. If exposed to chicken pox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chicken pox develops, treatment with antiviral agents may be considered. | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:indicatio... | Hydrocortisone tablets are indicated in the following conditions. | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:represent... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:routeOfAd... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:3494 | dailymed-instance:name | Hydrocortisone | lld:dailymed |
| http://www4.wiwiss.fu-berli... | dailymed-instance:producesD... | dailymed-drugs:3494 | lld:dailymed |
| diseasome-diseases:272 | diseasome-instance:possible... | dailymed-drugs:3494 | lld:diseasome |
| diseasome-diseases:2013 | diseasome-instance:possible... | dailymed-drugs:3494 | lld:diseasome |
| diseasome-diseases:116 | diseasome-instance:possible... | dailymed-drugs:3494 | lld:diseasome |
| diseasome-diseases:851 | diseasome-instance:possible... | dailymed-drugs:3494 | lld:diseasome |
| diseasome-diseases:710 | diseasome-instance:possible... | dailymed-drugs:3494 | lld:diseasome |
| diseasome-diseases:3047 | diseasome-instance:possible... | dailymed-drugs:3494 | lld:diseasome |
| diseasome-diseases:121 | diseasome-instance:possible... | dailymed-drugs:3494 | lld:diseasome |
| diseasome-diseases:1498 | diseasome-instance:possible... | dailymed-drugs:3494 | lld:diseasome |
| diseasome-diseases:1519 | diseasome-instance:possible... | dailymed-drugs:3494 | lld:diseasome |
| diseasome-diseases:3398 | diseasome-instance:possible... | dailymed-drugs:3494 | lld:diseasome |